Identification and validation the predictive biomarkers based on risk-adjusted control chart in gemcitabine with or without erlotinib for pancreatic cancer therapy

Identification and validation the predictive biomarkers based on risk-adjusted control chart in gemcitabine with or without erlotinib for pancreatic cancer therapy

BackgroundIn a randomized clinical controlled trial (PA.3) conducted by the Canadian Cancer Trials Group, the effects of gemcitabine combined with the targeted drug erlotinib (GEM-E) versus gemcitabine alone (GEM) on patients with unresectable, locally advanced, or metastatic pancreatic cancer were...

Full description

Saved in:
Bibliographic Details
Main Authors: Aijun Zhao, Dongsheng Tu, Ye He, Liu Liu, Bin Wu, Yixing Ren
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-12-01
Series:Frontiers in Genetics
Subjects:
pancreatic cancer
COX proportional hazards regression model
score test
risk-adjusted control chart
predictive biomarkers
Online Access:https://www.frontiersin.org/articles/10.3389/fgene.2024.1497254/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items